<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04976010</url>
  </required_header>
  <id_info>
    <org_study_id>EA2/162/17</org_study_id>
    <nct_id>NCT04976010</nct_id>
  </id_info>
  <brief_title>Single Cell Leukocyte Landscapes and Cardiovascular Risk in Children With Chronic Kidney Disease</brief_title>
  <official_title>Single Cell Leukocyte Landscapes and Cardiovascular Risk in Children With Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic kidney disease (CKD) is associated with an increased cardiovascular mortality. In&#xD;
      particular children with early-onset CKD have a lifelong increased risk to suffer from&#xD;
      cardiovascular disease (CVD). Therefore, children with CKD deserve our attention. The immune&#xD;
      system in children with CKD is disturbed, exhibiting pro-inflammatory features. Therefore, we&#xD;
      aim to learn more about the characteristics of the immune system in early-onset CKD. In this&#xD;
      project PBMC of pediatric CKD patients and age-matched healthy controls will be analysed and&#xD;
      compared using CITE-Seq as a multimodal scRNAseq phenotyping method. All patients will be&#xD;
      clinically characterized to integrate cardiovascular and immunological data.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Immunephenotyping of human PBMC</measure>
    <time_frame>at recruitment</time_frame>
    <description>scRNAseq with Cellular Indexing of Transcriptomes and Epitopes (CITE)-Seq for whole PBMC will be used to gain information on single cell transcriptomes across multiple immune cell populations together with expression levels of classical mmunological surface markers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microbiome sequencing of fecal samples</measure>
    <time_frame>at recruitment</time_frame>
    <description>16S RNA amplicon sequencing and whole genome shotgun sequencing will be perfomred in fecal samples, collected in RNA/DNA shield. This will allow us insights in composition (abundances) and function of the gut microbiome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Targeted metabolomics of plasma samples</measure>
    <time_frame>at recruitment</time_frame>
    <description>By using liquid-chromatography (LC) and gas-chromatography (GC) mass-spectrometry plasma samples will be analyzed for tryptophan metabolites and short chain fatty acids (absolute quantifiaction in µM).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse wave velocity</measure>
    <time_frame>at recruitment</time_frame>
    <description>The pulse wave velocity (m/s) will be measured in all recruited patients by usinfg the Mobilograph. Data will be normalized to age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carotid intima media thickness</measure>
    <time_frame>at recruitment</time_frame>
    <description>The carotid intima media thickness (mm) will be measured using ultrasound imaging of the carotid vessel. Data will be normalized to age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiography</measure>
    <time_frame>at recruitment</time_frame>
    <description>A basic echocardiography will be conducted evaluating diastolic and systolic, right and left ventricular function parameters.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Microbial Colonization</condition>
  <condition>Aging</condition>
  <arm_group>
    <arm_group_label>CKD G3-5</arm_group_label>
    <description>Patients with CKD and an estimated eGFR &lt; 60ml/min not yet on dialysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>End stage kidney disease (ESKD) CKD G5 Hemodialysis</arm_group_label>
    <description>Patients on hemodialysis for at least 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal kidney function</arm_group_label>
    <description>Patients enrolled with normal kidney function and/or CKD G1 and an estimated eGFR &gt; 90ml/min</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>There will be no intervention in the separate goups, as this is an observational study</description>
    <arm_group_label>CKD G3-5</arm_group_label>
    <arm_group_label>End stage kidney disease (ESKD) CKD G5 Hemodialysis</arm_group_label>
    <arm_group_label>Normal kidney function</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Fecal and blood samples will be collected at a single timepoint at study enrollment.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Only patients treated at the Department of Pediatric Nephrology in Berlin (Charité),&#xD;
        Hamburg (UKE) and Leipzig (KfH) will be recruited for this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  matching to one of the following groups CKD G3-5: estimated eGFR according to Schwartz&#xD;
             formula &lt;60ml/min*1,73m2 (no ESKD) CKD G5 D: patients with ESKD treated with&#xD;
             hemodialysis for at least 3 months normal kidney function: CKD G1 or no CKD with eGFR&#xD;
             &gt; 90ml/min*1,73m2&#xD;
&#xD;
          -  informed consent to participate in this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  body weight of less than 15kg&#xD;
&#xD;
          -  acute or chronic inflammatory diseases&#xD;
&#xD;
          -  fever&#xD;
&#xD;
          -  diabetes&#xD;
&#xD;
          -  chronic liver disease&#xD;
&#xD;
          -  inflammatory bowel disease or other gastrointestinal disorders (constipation,&#xD;
             diarrhea, short bowel syndrome)&#xD;
&#xD;
          -  antibiotic prophylaxis or treatment within four weeks prior to recruitment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominik Müller, MD</last_name>
    <role>Study Director</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Pediatric Gastroenterology, Nephrology and Metabolic Diseases, Charité-Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 3, 2021</study_first_submitted>
  <study_first_submitted_qc>July 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2021</study_first_posted>
  <last_update_submitted>July 14, 2021</last_update_submitted>
  <last_update_submitted_qc>July 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Johannes Benjamin Holle</investigator_full_name>
    <investigator_title>Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infections</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

